Curability and transferability of atopy with allogeneic hematopoietic cell transplantation

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F20%3A00013004" target="_blank" >RIV/00023736:_____/20:00013004 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1038/s41409-020-0876-7" target="_blank" >https://doi.org/10.1038/s41409-020-0876-7</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41409-020-0876-7" target="_blank" >10.1038/s41409-020-0876-7</a>

Result language
angličtina
Original language name
Curability and transferability of atopy with allogeneic hematopoietic cell transplantation
Original language description
Atopy is excessive production of IgE in response to allergens. We evaluated in patients undergoing allogeneic hematopoietic cell transplantation (HCT) the following hypotheses: (1) Atopy is “curable” in atopic patients receiving HCT from a nonatopic donor (D-R+), and (2) Atopy is transferable from atopic donors to nonatopic recipients (D+R-). Atopic patients with atopic donors (D+R+) and non-atopic patients with non-atopic donors (D-R-) served as controls. We measured levels of multiallergen-specific IgE (A-IgE, atopy defined as ≥0.35 kUA/L) in sera from 54 patients and their donors pre HCT and from the patients at ≥2 years post HCT. Only 7/12 (58%) D− R+ patients became nonatopic after HCT.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)